Update on the Management of Connective Tissue Malignancies

Seminars in Oncology

Volumn 31, Issue 2 SUPPL. 4, 2004, Pages 16-19

  Fanucchi, Michael ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; MESNA; SUNITINIB; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONFERENCE PAPER; CONNECTIVE TISSUE; DOSE RESPONSE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; METASTASIS; MULTIMODALITY CANCER THERAPY; OSTEOSARCOMA; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

EID: 2342550634     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.02.010     Document Type: Conference Paper

References (27)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics 2003. Cancer J Clin 53:5-26, 2003
2. Weiss SW, Goldblum JR: Enzinger and Weiss's Soft Tissue Tumors (ed 4). St Louis, MO, 2001
3. American Joint Committee on Cancer: AJCC Cancer Staging Manual. New York, NY, AJCC, Springer-Verlag, 2002
4. Suit HD, Mankin HJ, Wood WC, et al: Treatment of the patient with stage MO soft tissue sarcoma. J Clin Oncol 6:854-862, 1988
5. O'Sullivan B, Davis AM, Turcotte R, et al: Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 359:2235-2241, 2002
6. Sarcoma Meta-analysis Collaboration: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Lancet 350:1647-1654, 1997
7. Frustaci S, Gherlinzoni F, De Paoli A, et al: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial. J Clin Oncol 19:1238-1247, 2001
8. DeLaney TF, Spiro IJ, Suit HD, et al: Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 56:1117-1127, 2003
9. Kraybill WG, Harris JH, Spiro I, et al: Radiation Therapy Oncology Group (RTOG) 9514: A phase II study of neoadjuvant chemotherapy (CT) and radiation therapy (RT) in the management of high risk (HR), high grade, soft tissue sarcomas (STS) of the extremities and body wall. Proc Am Soc Clin Oncol 22:815, 2003 (abstr)
10. Grobmyer SR, Maki R, Demetri GD, Riedel E, Brennan MF, Singer S. Neo-adjuvant chemotherapy for primary high grade extremity soft tissue sarcoma: A matched case control study. Proc Am Soc Clin Oncol 22:815, 2003 (abstr)
11. Le Cesne A, Judson I, Crowther D, et al: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/ Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18:2676-2684, 2000
12. Patel SR, Vadhan-Raj S, Burgess MA, et al: Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 21:317-321, 1998
13. Worden FP, Taylor JMG, Bierman JS, et al: A randomized phase II evaluation of standard dose ifosfamide (Ifos) plus doxorubicin (Dox) versus high dose ifosfamide plus Dox in patients with high-grade soft tissue sarcomas. Proc Am Soc Clin Oncol 22:817, 2003 (abstr)
14. Hensley ML, Maki R, Venkatraman E, et al: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824-2831, 2002
15. Crist WM, Anderson JR, Meza JL, et al: Intergroup Rhabdomyosarcoma. Study-IV: Results for patients with non-metastatic disease. J Clin Oncol 19:3091-3102, 2001
16. Breneman JC, Lyden E, Pappo AS, et al: Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21:78-84, 2003
17. Goorin AM, Schwartzentruber DJ, Devidas M, et al: Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574-1580, 2003
18. Goorin AM, Harris MB, Bernstein M, et al: Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial. J Clin Oncol 20:426-433, 2002
19. Grier HE, Krailo MD, Tarbell NJ, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694-701, 2003
20. Pakos EE, Ioannidis JP: The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer 98:581-589, 2003
21. Edmonson JH, Marks RS, Buckner JC, et al: Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 20:605-612, 2002
22. Heinrich MC, Corless CL, Mehren MV, et al: PDGFRA and kit mutations correlate with the clinical responses to imatinib mesylate in patients with advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol 22:815, 2003 (abstr)
23. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
24. Verweij J, Casali PG, Zalcberg J, et al: Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc Am Soc Clin Oncol 22:814, 2003 (abstr)
25. Benjamin RS, Rankin C, Fletcher C, et al: Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 22:814, 2003 (abstr)
26. Fletcher JA, Corless CL, Dimitrijevic S, et al: mechanisms of resistance to imatinib mesylate (IM) IN advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 22:814, 2003 (abstr)
27. Demetri GD, George S, Heinrich MC, et al: Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol 22:814, 2003 (abstr)